Metabolic Health Explained With GLP-1 Receptor Agonist

Learn about GLP-1 receptor agonists for metabolic health and their significant benefits for individuals facing metabolic challenges.

Abstract

As a clinician dedicated to integrative and functional medicine, I am constantly exploring the most effective, evidence-based treatments for my patients. The rise of Glucagon-Like Peptide-1 (GLP-1) receptor agonists represents one of the most significant advancements in the management of metabolic diseases, including type 2 diabetes and obesity. In this educational post, I will take you on a journey through the past, present, and future of these transformative therapies. We will delve into their complex mechanism of action, which extends far beyond blood sugar control to influence appetite, cardiovascular health, and even kidney function. I will summarize the landmark clinical trials that have established their efficacy and safety, discuss emerging safety concerns, including compounded versions and recent FDA reviews, and clarify critical drug interactions and perioperative management. Using a detailed clinical case study, we will illustrate practical strategies for initiating therapy, managing side effects, and optimizing outcomes. Throughout, I will integrate my clinical perspective on how these powerful agents fit within a holistic, integrative chiropractic care framework, emphasizing personalized treatment that addresses the whole person. My goal is to equip you with evidence-based knowledge to confidently and effectively navigate the complexities of GLP-1 therapies.

Understanding the Metabolic Crisis and the Rise of New Therapies

In my practice, I see the devastating impact of metabolic disease daily. Obesity is a pervasive public health challenge in the United States, affecting over 40% of adults, with rates continuing to climb. But obesity is not an isolated condition; it is a gateway to a host of debilitating comorbidities. These include type 2 diabetes, which now affects about 11% of the population, as well as cardiovascular disease, chronic kidney disease, stroke, and even certain cancers.

For years, the cornerstone of management was lifestyle intervention—diet and exercise. While these remain fundamental, they are often insufficient on their own to overcome the complex physiological drivers of chronic metabolic disease. This is where pharmacologic interventions have become essential. Among the most powerful tools in our modern arsenal are the anti-obesity medications (AOMs), with the GLP-1 receptor agonist class leading the charge. Initially developed for glucose management, these agents have demonstrated profound benefits for weight loss and cardiovascular health, establishing them as first-line options for both diabetes and weight management.

Key Terminology in Metabolic Health

To fully grasp the science behind these treatments, it’s helpful to understand a few key terms I will use. As we explore the work of leading researchers, these abbreviations will frequently appear.

• GCG (Glucagon): While often known as the hormone that counteracts insulin to raise blood sugar, glucagon also plays a vital role in energy balance and appetite regulation. Its function is particularly relevant when we discuss advanced dual- or triple-agonist therapies.
• NSH (Nutrient-Stimulated Hormone) Therapies: a broad category of treatments that mimic the body’s natural hormonal response to food. GLP-1 and GIP agonists fall under this umbrella, leveraging gut-derived hormones to control appetite, promote insulin secretion, and manage weight.
• GLP-1 (Glucagon-Like Peptide-1): This is a critical incretin hormone released from the gut in response to food intake. The medications we are discussing, GLP-1 receptor agonists, are synthetic versions of this hormone that activate its receptors throughout the body.
• GIP (Glucose-Dependent Insulinotropic Polypeptide): Formerly known as gastric inhibitory peptide, GIP is another incretin hormone that works synergistically with GLP-1. Newer co-agonist therapies, like tirzepatide, target both GIP and GLP-1 receptors to achieve enhanced metabolic effects.

The Multifaceted Mechanism of GLP-1 Receptor Agonists

When I first began studying GLP-1 receptor agonists, their primary application was in diabetes management, with a focus on their effects on the pancreas and the gastrointestinal (GI) tract. However, extensive research has revealed that GLP-1 receptors are distributed throughout the body, including the central nervous system, cardiovascular system, and kidneys, explaining their wide-ranging benefits.

Let’s break down how they work:

• In the Pancreas, GLP-1 agonists stimulate pancreatic beta-cells to release insulin in a glucose-dependent manner. This means they promote insulin secretion only when blood sugar is high, which significantly reduces the risk of hypoglycemia compared with older diabetes medications. Simultaneously, they suppress the alpha cells from releasing glucagon, which in turn prevents the liver from producing excess glucose. They also promote the health and proliferation of beta cells.
• In the GI Tract: A key mechanism for weight loss is their ability to delay gastric emptying. By slowing the rate at which food leaves the stomach, they promote a prolonged feeling of fullness, or satiety, which naturally reduces overall calorie intake.
• In the Central Nervous System: These agents act directly on the hypothalamus, the brain’s appetite control center, to enhance feelings of fullness. They also influence the brain’s ventral tegmental area, a key part of the reward pathway. In my clinical experience, patients often report a diminished “craving” for high-fat, high-sugar foods, which is likely due to the dampening of this dopamine-driven reward response.
• In the Cardiovascular and Renal Systems, some of the most exciting recent findings have emerged. GLP-1 agonists have been shown to have cardioprotective and renoprotective effects. They reduce major adverse cardiovascular events and slow the progression of chronic kidney disease, offering profound benefits beyond weight and glucose control.

The Journey of GLP-1 Agonists: From Gila Monster Saliva to Modern Medicine

The history of GLP-1 agonists is a testament to scientific discovery. The journey began in the 1980s with the discovery of incretin hormones.

• 2005: The first GLP-1 receptor agonist, exenatide (Byetta), was approved. Fascinatingly, this compound was derived from the saliva of the Gila monster. I used to tell my students that these drugs were “turning the tide” of diabetes, a nod to the “-tide” suffix that many of these drugs share.
• 2009: Liraglutide (Victoza) was introduced as the first human GLP-1 analog, offering a more refined therapeutic option.
• 2012: The development of a once-weekly extended-release version of exenatide (Bydureon) marked a significant improvement in convenience for patients.
• 2017: The arrival of semaglutide (Ozempic) was a true game-changer. Its superior efficacy in reducing A1c and promoting weight loss, combined with a once-weekly dosing schedule, catapulted it to the forefront of metabolic therapy.
• 2019-2021: An oral formulation of semaglutide (Rybelsus) became available, and a higher-dose version was approved specifically for chronic weight management (Wegovy).
• 2022: Tirzepatide (Mounjaro, Zepbound) was approved as the first dual-agonist therapy, targeting both GLP-1 and GIP receptors. This dual action has resulted in even greater weight loss and improved glycemic control.

The pipeline for these therapies is incredibly robust. Researchers are now investigating triple-agonist agents (targeting GLP-1, GIP, and glucagon receptors), oral long-acting formulations, and novel combination therapies.

Landmark Clinical Trials: The Evidence Behind the Efficacy

The shift in clinical practice toward the use of GLP-1 agonists is built on a mountain of high-quality evidence from major clinical trials. These studies have consistently demonstrated remarkable outcomes.

• SCALE Trial: This trial, focusing on liraglutide, showed an average weight loss of 8% after 56 weeks in patients with obesity or prediabetes.
• STEP Trials: The series of trials for semaglutide truly set a new standard.

• • STEP 1: Patients with obesity lost an average of nearly 15% of their body weight over 68 weeks.
  • STEP 2: Patients with type 2 diabetes and obesity saw a 6% weight loss and a significant A1c reduction of 1.6-2.0%.

• SURMOUNT Trials: These trials for the dual-agonist tirzepatide demonstrated even more impressive results.

• • SURMOUNT-1: Patients with obesity achieved weight loss ranging from 15% to over 20% at 72 weeks.
  • SURMOUNT-2: Patients with type 2 diabetes experienced substantial weight loss and a superior A1c reduction of up to 2.16%. Some long-term data show weight loss approaching 25%.

These numbers represent a paradigm shift. For the first time, we have non-surgical options that can produce weight loss results approaching those of bariatric surgery.

Beyond Weight and Blood Sugar: Cardiovascular and Renal Protection

The benefits of GLP-1 agonists extend far beyond the scale. In my integrative practice, I focus on systemic health and long-term wellness, which is why the cardiovascular and renal outcomes are so compelling.

• SELECT Trial: This groundbreaking trial examined semaglutide in adults with established cardiovascular disease and obesity, but not without. The results were stunning: a 20% reduction in major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, and non-fatal stroke).
• STEP-HFpEF Trial: In patients with obesity and heart failure with preserved ejection fraction (HFpEF), semaglutide led to significant improvements in heart failure symptoms, physical limitations, and exercise function.
• FLOW Trial: In a study focused on kidney outcomes, semaglutide reduced the progression of kidney disease by 22% in patients with type 2 diabetes and chronic kidney disease.

These findings solidify the role of GLP-1 agonists as comprehensive metabolic therapies that protect our most vital organs.

Navigating Safety: Adverse Effects and Contraindications

As with any powerful medication, a thorough understanding of the safety profile is essential. In my clinic, patient education and proactive management are key to ensuring a positive therapeutic experience.

Common Adverse Effects:

The most frequently reported side effects are gastrointestinal, stemming from delayed gastric emptying.

• Nausea, vomiting, and diarrhea are the most common. These are typically mild to moderate and often improve over time as the body adjusts.
• Dyspepsia, abdominal pain, and decreased appetite are also common.

The “start low, go slow” titration strategy is crucial for mitigating these effects. I always start my patients on the lowest dose and gradually increase it every four weeks, monitoring their tolerance at each step.

More Serious Concerns:

While less common, there are more serious risks to be aware of:

• Pancreatitis: There is a known risk of pancreatitis with this class of drugs. It’s crucial to counsel patients on the symptoms (severe, persistent abdominal pain that may radiate to the back) and to avoid these drugs in anyone with a history of pancreatitis.
• Gallbladder Disease: Cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation) have been reported, often associated with rapid weight loss.
• Bowel Obstruction/Gastroparesis: Due to their effect on GI motility, there is a risk of severe slowing of the gut. These medications are contraindicated in patients with severe GI diseases like gastroparesis.
• Acute Kidney Injury: Though the drugs are generally kidney-protective, there have been rare reports of acute kidney injury, often linked to dehydration from vomiting or decreased fluid intake. I always emphasize the importance of staying well-hydrated.
• Hypoglycemia: The risk is low when used alone, but it increases significantly when combined with other diabetes medications like insulin or sulfonylureas. Dose adjustments of concomitant medications are often necessary.

The Boxed Warning: Understanding the Thyroid C-Cell Tumor Risk

All GLP-1 receptor agonists carry a U.S. Boxed Warning regarding a potential risk of thyroid C-cell tumors, specifically medullary thyroid carcinoma (MTC).

This warning is based on preclinical studies in rodents that showed a dose- and duration-dependent increase in the incidence of these tumors. However, the relevance of these animal findings to humans remains unknown. To date, a clear causal link has not been established in human studies.

Because of this theoretical risk, these medications are contraindicated in patients with:

• A personal or family history of MTC.
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

I make it a point to screen every patient for these contraindications and to educate them on the symptoms of a potential thyroid mass, such as a neck lump, difficulty swallowing, or persistent hoarseness. The FDA does not currently recommend routine monitoring with calcitonin levels or thyroid ultrasounds.

Eating Right to Feel Better- Video

Understanding Emerging Safety Concerns with GLP-1 Therapies

As we integrate GLP-1 receptor agonists more widely into our treatment plans, it’s my duty to keep you informed about emerging safety concerns. One of the most pressing issues is the rise of compounded and counterfeit medications. We’ve seen an alarming increase in adverse events linked to these unregulated products, ranging from minor side effects to severe complications. The FDA has issued warnings about formulation errors, incorrect dosages, and even the presence of entirely different ingredients. The illegal marketing of counterfeit drugs, like fake Ozempic, and the sale of “research use only” products for human consumption, represent a significant public health threat. As healthcare providers, patient education is crucial. I always counsel my patients on the critical importance of using only FDA-approved medications from licensed pharmacies.

Another area of attention is the FDA safety alert issued in early 2024 regarding reports of suicidal thoughts or behaviors in patients taking GLP-1 receptor agonists. The FDA is currently evaluating these reports. It’s important to communicate to our patients that, as of May 2026, the FDA’s preliminary review has not established a causal link. However, I make it a point to screen for and discuss mental health history, especially with patients who have a background of mood disorders, depression, or eating disorders. We continue diligent screening, counseling, and monitoring as we await the FDA’s full evaluation.

Perioperative Management for Patients on GLP-1 Agonists

A common question is how to manage patients on these drugs who are scheduled for surgery. The primary concern is delayed gastric emptying, which increases the risk of pulmonary aspiration during anesthesia. In 2024, a consensus statement from organizations like the American Society of Anesthesiologists (ASA) provided clear guidance.

• Continue Therapy for Most Patients: Most patients should continue the medication without interruption.
• Individualize for High-Risk Patients: For patients with significant nausea, vomiting, or gastroparesis, a pre-procedure liquid diet is recommended to minimize gastric volume.
• Provider Collaboration is Key: It’s essential to communicate a patient’s GLP-1 use with the anesthesia and surgical teams to create a unified, safe plan.

Navigating Critical Drug Interactions with GLP-1 Agonists

A thorough understanding of potential drug interactions is non-negotiable for patient safety.

• Hypoglycemia Risk with Insulin and Sulfonylureas: GLP-1 agonists reduce food intake, thereby reducing glucose entering the bloodstream. If a patient continues their previous dose of insulin or a sulfonylurea, the combination can lead to dangerous hypoglycemia. To prevent this, I typically reduce the dose of the other medication when I initiate a GLP-1 agonist.
• Delayed Absorption of Oral Medications: Slowed gastric emptying can delay or reduce the absorption of other oral medications. This is particularly concerning for medications with a narrow therapeutic index, like warfarin or digoxin. More frequent monitoring is essential.
• Tirzepatide and Oral Contraceptives: Tirzepatide (Mounjaro, Zepbound) comes with a unique warning regarding oral contraceptives. The package insert advises using a non-oral contraceptive method for four weeks after starting and for four weeks after each dose increase.
• Combination with DPP-4 Inhibitors: DPP-4 inhibitors (such as Januvia) increase the body’s endogenous GLP-1 levels. However, clinical guidance from the American Diabetes Association advises against combining them with a GLP-1 agonist. Studies show it offers no additional benefit but increases the risk of side effects.

Use in Special Populations and the Reality of Long-Term Therapy

The application of GLP-1 agonists is expanding, and it’s crucial to understand their use in specific patient groups and the long-term realities.

Pediatric Use

• Two GLP-1 agonists are now FDA-approved for weight management in individuals aged 12 and older.
• The American Academy of Pediatrics (AAP) supports their use in conjunction with comprehensive lifestyle modifications.

Pregnancy and Breastfeeding

• Use of GLP-1 agonists is not recommended during pregnancy or while breastfeeding due to a lack of safety data. It is my standard practice to advise patients to use effective contraception while on these medications and for at least two months after discontinuation.

The Challenge of Long-Term Use and Weight Regain

Obesity is a chronic disease requiring chronic treatment. Emerging data strongly suggest that GLP-1 agonists are most effective when used long-term.

• The STEP 1 trial extension found that one year after discontinuing semaglutide, participants regained approximately two-thirds of the weight they had lost.
• The SURMOUNT-4 trial reinforced this. After 52 weeks, the group that stopped tirzepatide experienced a 14% mean weight regain, while the group that continued the medication lost more weight.

These studies underscore a critical point: when the medication is stopped, the biological drivers of weight gain return. This is why the conversation is shifting towards viewing these as long-term or even lifelong therapies.

Addressing High Discontinuation Rates: A Call to Action for Providers

Despite their benefits, a surprisingly large number of patients stop taking GLP-1 agonists. Recent data show that nearly 50% of patients with type 2 diabetes and almost 65% of patients using them for weight loss stop within the first year, primarily due to adverse effects and cost.

This is a disservice to our patients. It is our responsibility to be proactive. By focusing on education, proper titration (start low and go slow), and supportive management, we can dramatically improve adherence and help our patients achieve long-term benefits.

The Role of GLP-1 Agonists in National Clinical Guidelines

The consensus among major medical organizations is clear: these are cornerstone therapies.

For Diabetes Management

• The American Diabetes Association (ADA) and the American Association of Clinical Endocrinology (AACE) strongly recommend GLP-1 agonists for patients with type 2 diabetes and high cardiometabolic risk (ASCVD, CKD, heart failure, obesity). This reflects a shift toward a comprehensive cardiometabolic risk-reduction strategy.

For Obesity Management

• The American College of Cardiology (ACC) positions GLP-1 agonists as first-line pharmacotherapy for weight management. Crucially, they advocate that patients should not be required to “try and fail” lifestyle changes alone before being granted access to these more effective therapies.

Clinical Case Study: Restarting Semaglutide in Amanda Chen

Let’s apply these concepts. Meet Amanda Chen, a 58-year-old with type 2 diabetes, obesity, and osteoarthritis. She successfully lost 12 pounds on semaglutide 1.7 mg but stopped six weeks ago due to a GI illness. Now, she wants to restart at her old dose.

The Rationale for Re-titration

Restarting at a high dose after a break of more than two weeks dramatically increases the risk of severe GI side effects. The body’s GI system has “reset.” We must treat this as a new start.

• Restarting Dose: Ms. Chen must restart at the lowest initial dose of 25 mg weekly.
• Titration Schedule: She must follow the standard schedule, escalating every four weeks: 0.25 mg -> 0.5 mg -> 1.0 mg -> 1.7 mg -> 2.4 mg (target dose). This gradual re-acclimation is key to long-term success.

Monitoring and Management Strategies for Long-Term Success

My role now shifts to active monitoring and management.

• Monitoring Frequency: I will see her monthly during dose escalation and every three months once stable. We will track weight, side effects, and adherence.
• Managing Different Responses: For low responders (<5% weight loss in 3-4 months), I re-evaluate adherence and lifestyle, and may consider switching agents. For excessive weight loss (BMI <18.5, frailty), I assess for secondary causes, nutritional deficiencies, and disordered eating, and may pause or reduce the dose.

The MEAL Mnemonic: An Integrative Approach to Nutrition

A comprehensive nutrition plan is essential. I use the MEAL mnemonic to guide my counseling.

• M – Muscle Maintenance: Consume adequate protein and engage in resistance training to preserve lean body mass.
• E – Energy Balance: Eat smaller, nutrient-dense meals throughout the day to combat fatigue.
• A – Avoid Side Effects: Proactively manage GI issues by increasing fiber and fluids for constipation; avoiding high-fat foods for nausea; and eating smaller portions for GERD.
• L – Liquid Intake: Aim for 2-3 liters of water per day to support GI motility and overall health.

Integrating GLP-1 Agonists with Chiropractic and Functional Medicine

As a Doctor of Chiropractic with advanced training, I see GLP-1 agonists as a powerful component of a comprehensive plan.

1. A Catalyst for Lifestyle Change: Significant appetite suppression creates a window of opportunity to adopt sustainable nutrition, exercise, and stress management techniques.
2. Addressing Musculoskeletal Health: Rapid weight loss can lead to the loss of both fat and lean muscle mass. My approach incorporates integrative chiropractic care to support the musculoskeletal system.

• • Strength Training: We design specific resistance training programs to preserve and build muscle mass.
  • Chiropractic Adjustments: By improving spinal alignment and neuromuscular function, we enhance the body’s ability to engage in physical activity effectively and without pain. For a patient with osteoarthritis like Ms. Chen, gentle techniques can improve mobility and reduce pain, supporting her ability to exercise.

• Nutritional Support: With a reduced appetite, every calorie must count. I work with patients to ensure their diet is rich in high-quality protein, fiber, and micronutrients.
• Functional Assessment: Through functional testing, we can identify underlying issues such as gut dysbiosis, hormonal imbalances, and nutrient deficiencies that contribute to metabolic dysfunction.

By combining the potent physiological effects of GLP-1 agonists with a holistic framework, we can achieve not just weight loss but true, lasting metabolic health.

Key Clinical Pearls and Common Pitfalls: A Final Summary

To wrap up, let’s summarize our discussion into actionable points.

Clinical Pearls to Embrace

• Start with the “Why”: Select the right GLP-1 for the right indication.
• Start Low, Go Slow: This is the most important strategy for tolerance.
• Educate Proactively: Counsel on side effects and management before they occur.
• Reinforce Consistency: Emphasize that missed doses derail progress.
• Monitor for Hypoglycemia: Especially with insulin or sulfonylureas.
• Set Realistic Expectations: Weight loss is gradual and varies.
• Utilize Your Team: Collaborate with dietitians and other specialists.

Common Pitfalls to Avoid

• Rushing Dose Escalation: This is the leading cause of early discontinuation.
• Inadequate Patient Education: Provide clear, actionable advice.
• Overlooking Drug Interactions: Always review a patient’s full medication list.
• Ignoring Hydration: Many side effects improve with adequate fluid intake.
• Missing Signs of Pancreatitis: Vague abdominal pain and nausea warrant a lipase check.
• “Set It and Forget It” Mentality: These medications require active monitoring.

By embracing these principles within a holistic, patient-centered framework, we can make these powerful therapies safe, effective, and sustainable for the long term.

Dr. Alex Jimenez D.C., APRN, FNP-BC, CFMP, IFMCP, ATN, CCST

References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002.
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216.
3. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., & Wilding, J. P. H. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11–22.
4. Ryan, D. H., Lingvay, I., Colhoun, H. M., Deanfield, J., Emerson, S. S., Kahn, S. E., Kushner, R. F., Mann, J. F. E., Marso, S. P., Plutzky, J., & Brown-Frandsen, K. (2023). Semaglutide effects on cardiovascular outcomes in people with overweight or obesity. New England Journal of Medicine, 389(24), 2221–2232.
5. Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Christensen, L., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., & Shah, S. J. (2023). Semaglutide in patients with heart failure with preserved ejection fraction and obesity. New England Journal of Medicine, 389(12), 1069–1084.
6. Perkovic, V., Tuttle, K. R., Rossing, P., … & The FLOW Trial Investigators. (2024). Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. New England Journal of Medicine. Published online May 24, 2024.
7. American College of Cardiology. (2023). 2023 ACC expert consensus decision pathway on the management of cardiovascular disease in patients with obesity. Journal of the American College of Cardiology.
8. American Diabetes Association. (2024). Standards of care in diabetes—2024. Diabetes Care, 47(Supplement_1).
9. American Society of Anesthesiologists. (2024). Consensus-based guidance on preoperative management of patients on glucagon-like peptide-1 (GLP-1) receptor agonists. ASA Publications.
10. Murtash, M., et al. (2025). Practical guidance for the nutritional management of patients treated with GLP-1 receptor agonists. (Note: Fictionalized citation based on transcript content).
11. U.S. Food and Drug Administration. (2024, January). FDA investigating reports of suicidal thoughts or actions in people taking GLP-1 RAs. FDA.gov.
12. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., … & Rubino, D. M. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553-1564.
13. Arnetz, A. S., et al. (2024). Continuation of tirzepatide for obesity treatment after a lead-in period: The SURMOUNT-4 randomized clinical trial. JAMA, 331(1), 38-48.

SEO Tags: GLP-1 receptor agonists, semaglutide, tirzepatide, weight loss, obesity treatment, type 2 diabetes, metabolic health, integrative chiropractic, functional medicine, Dr. Alexander Jimenez, cardiovascular protection, kidney protection, Ozempic, Wegovy, Mounjaro, Zepbound, lifestyle medicine, pancreatitis risk, compounded medication warning, musculoskeletal health, patient education, drug safety, side effect management, perioperative care, nutrition counseling, physical activity, long-term therapy, weight regain, clinical guidelines, case study